OpenLegislation

The Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2009

S.R. 2009/390 · Made 25 November 2009 · Extends to Northern Ireland

Up to date with all changes known to legislation.gov.uk, revised to 23 December 2009.

Dangerous Drugs

Made 25th November 2009

Coming into operation 23rd December 2009

The Department of Health, Social Services and Public Safety makes the following Regulations in exercise of the powers conferred by sections 7, 10, 22 and 31 of the Misuse of Drugs Act 1971f1 as adapted by section 38 of that Act and now vested in itf2.

In accordance with section 31(3) of that Act, it has consulted with the Advisory Council on the Misuse of Drugs.

Annotations to the whole text

Footnotes

f1

1971 c.38 Section 22 of that Act was amended by section 177(1) of, and paragraph 12 of Schedule 4 to, the Customs and Excise Management Act 1979(c.2)

f2

S.R. & O.(N.I) 1973 No 504; Article 5(a) and S.I.1999 No 283(N.I.1), Article 3(6)

Contents

  1. 1Citation and Commencement
  2. 2Interpretation
  3. 3Amendments to the 2002 Regulations
  4. 4Regulation 4 Repealed
  5. 5Regulation 5
  6. Signature
  7. Explanatory note

1Citation and CommencementI1

These Regulations may be cited as the Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2009 and shall come into operation on 23rd December 2009.

2InterpretationI1

(1)

In these Regulations, “the 2002 Regulations” means the Misuse of Drugs Regulations (Northern Ireland) 2002f1

(2)

The Interpretation Act (Northern Ireland) 1954f2 shall apply to these Regulations as it applies to an Act of the Assembly.

3Amendments to the 2002 RegulationsI1

The 2002 Regulations shall be amended as follows.

4F1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

5I1

(1)

In Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27)—

(a)

in paragraph 1(a)—

(i)

after “Concentrate of poppy-straw”, insert—

“[2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1,2,3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone

3–Dimethylheptyl–11–hydroxyhexahydrocannabinol”;

(ii)

after “Fungus (of any kind) which contains psilocin or an ester of psilocin”f1, insert—

“[9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate

9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol”;

(b)

after paragraph 1(f), insert—

“(g)

1–benzylpiperazine or any compound (not being a compound for the time being specified in Schedule 4) structurally derived from 1–benzylpiperazine or 1–phenylpiperazine by modification in any of the following ways—

(i)

by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups;

(ii)

by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl groups;

(h)

any compound structurally derived from 3–(1–naphthoyl)indole or 1H–indol–3–yl–(1–naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

(i)

any compound structurally derived from 3–(1–naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

(j)

any compound structurally derived from 1–(1–naphthylmethyl)indene by substitution at the 3–position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent;

(k)

any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;

(l)

any compound structurally derived from 2–(3–hydroxycyclohexyl)phenol by substitution at the 5–position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.”

(2)

In paragraph 1 of Schedule 2 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 21, 23, 26 and 27)—

(a)

after “Myrophine”, insert “Nabilone”;

(b)

after “Norpipanone”, insert “Oripavine”.

(3)

In paragraph 1 of Part 1 of Schedule 4 (which specifies controlled drugs subject to the requirements of regulations 22, 23, 26 and 27), after “Chlordiazepoxide”, insert—

“1–(3–chlorophenyl)piperazine

1–(3–chlorophenyl)–4–(3–chloropropyl)piperazine”.

(4)

In Part 2 of Schedule 4 (controlled drugs excepted from the prohibition on possession when in the form of a medicinal product)—

(a)

in paragraph 1—

(i)

before “4–Androstene–3,17–dione”f2, insert—

“5α–Androstane–3,17–diol

Androst-4-ene-3,17-diol

1–Androstenediol

1–Androstenedione”;

(ii)

after “4–Androstene–3,17–dione”, insert “5–Androstenedione”;

(iii)

after “Boldenone”, insert “Boldione”;

(iv)

after “Clostebol”, insert—

“Danazol

Desoxymethyltestosterone”;

(v)

after “Furazabol”, insert—

“Gestrinone

3–Hydroxy–5α–androstan–17–one”;

(vi)

after “Nandrolone”, insert “19–Norandrostenedione”;

(vii)

after “19–Nor–5–Androstene–3,17–diol”f3, insert “19–Norandrosterone”;

(viii)

after “Norethandrolone”, insert “19–Noretiocholanolone”;

(ix)

after “Propetandrol”, insert “Prostanozol”;

(x)

after “Testosterone”, insert “Tetrahydrogestrinone”;

(b)

in paragraph 4, after “Somatropin”, insert—

“Zeranol

Zilpaterol”.

Signature

Sealed with the Official Seal of the Department of Health, Social Services and Public Safety on 25th November 2009

(L.S.)

Norman Morrow

A Senior Officer of the Department of Health, Social Services and Public Safety

Explanatory note

(This note is not part of the Regulations)

These Regulations insert 1–benzylpiperazine (BZP), all but two of a group of substituted piperazines and the synthetic cannabinoid agonists into Schedule 1 to the Misuse of Drugs Regulations (Northern Ireland) 2002 (“the 2002 Regulations”), save for Nabilone which is inserted into Schedule 2 to the 2002 Regulations along with Oripavine. The two other substituted piperazines are inserted into Part 1 of Schedule 4 to the 2002 Regulations and 15 anabolic steroids and 2 non-steroidal agents are inserted into Part 2 of that Schedule. The schedule in which a controlled drug is placed primarily affects the extent to which the drug can be lawfully imported, exported, produced, supplied or possessed and dictates the record keeping, labelling and destruction requirements in relation to those drugs.

Gamma–butyrolactone (GBL) and 1, 4–butanediol (1, 4–BD) are not inserted into any schedule. However, regulation 4 makes it lawful to import, export, produce, supply, offer to supply or possess these substances except where a person does so, knowing or believing that it will be used for the purpose of human ingestion.